Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form

10.4088/JCP.v63n1007

Blackwell B, 1996, A quarter century of research. Neth J Med, 48, 140

Fleischhacker WW, 2003, Factors influencing compliance in schizophrenia patients. J Clin Psychiatry, 64, 10

10.1176/ps.49.2.196

10.4088/JCP.v63n1206

10.1185/030079902125000840

10.1002/1099-081X(200001)21:1<23::AID-BDD212>3.0.CO;2-V

10.1046/j.1365-2125.2002.01599.x

10.1002/jps.2600641218

10.1161/01.HYP.0000107251.49515.c2

10.1001/archinte.1991.00400020026007

Frishman WH, 1985, J Clin Hypertens, 1, 107

Furberg CD, 1995, Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation, 92, 1326

Grundy JS, 1996, Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin Pharmacokinet, 30, 28

Chung M, 1987, A controlled-release formulation of nifedipine. Am J Med, 83, 10

Mohiuddin S, 1991, Curr Ther Res, 50, 546

van Zwieten PA, 1993, J Hypertens Suppl, 11, S3–S11

Glasser SP, 1999, Heart Dis, 1, 226

10.1016/S0002-8703(02)00137-0

Type Quinn L., 2001, Nurs Clin North Am, 36, 175, 10.1016/S0029-6465(22)02543-9

10.7326/0003-4819-131-4-199908170-00008

Simonson DC, 1997, Results of two multicenter, randomized, placebo-controlled clinical trials [The Glipizide Gastrointestinal Therapeutic System Study Group]. Diabetes Care, 20, 597

Berger W, 1997, Schweiz Rundsch Med Prax, 86, 308

10.1177/00970002042006007

10.2337/diacare.17.12.1460

10.1023/A:1017595818158

10.1046/j.1365-2125.1999.00067.x

10.1016/S0022-5347(01)65193-0

Fulton B, 1995, Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs, 49, 295

Andersen M, 2000, Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol, 38, 400

10.1111/j.1464-410X.2005.05342.x

10.1046/j.1464-410x.2001.02032.x

10.1185/030079904125003593

10.1111/j.1471-0528.1997.tb12054.x

10.1097/00003081-200203000-00022

Gupta SK, 1999, J Clin Pharmacol, 39, 289, 10.1177/009127009903900313

Siddiqui MA, 2004, Scott LJ. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs, 64, 885

10.2165/00003088-200443140-00008

10.1177/0091270005278055

Sathyan G, 1999, Pharm Sci, 1, 2056

10.1016/S0022-5347(05)68810-6

10.1016/S0029-7844(99)00661-4

10.1023/A:1021372426421

Kane J, 2005, Neuropsychopharmacology, 30, S200

Davidson M, 2006, Schizophr Res, 81, S43

Marder S, 2005, Neuropsychopharmacology, 30, S191–S192

10.2165/00023210-200418040-00004

10.2165/00023210-200418140-00005

Attention-deficit/hyperactivity Biederman J., 1998, J Clin Psychiatry, 59, 4

10.2165/00023210-200317020-00004

10.1176/appi.ajp.160.11.1909

Jr WE Pelham, 1987, Pediatrics, 80, 491, 10.1542/peds.80.4.491

10.1089/cap.1990.1.7

Pelham WE, 2001, Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics, 107, E105

10.1542/peds.108.4.883

10.1097/01.CHI.0000046814.95464.7D

Baren M, 2000, Pediatr Res, 47, 23A

10.1542/peds.113.3.e206

Fenton WS, 1991, II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry, 48, 978

10.1111/j.1600-0447.1999.tb10829.x

APA, 2002, Am J Psychiatry, 159, 1

10.1176/appi.ajp.159.10.1653

Fenton WS, 1997, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull, 23, 637

10.1034/j.1600-0447.2000.00016.x

Gerlach J, 1999, J Clin Psychiatry, 60, 20

10.1176/appi.ajp.157.4.514

Ereshefsky L, 2003, J Clin Psychiatry, 64, 18

10.4088/JCP.v62n0303

10.1016/S0885-3924(02)00643-7

10.1002/j.1552-4604.1981.tb05693.x

10.1097/00000542-200210000-00013

Bass DM, 2002, Waxman DS. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS: a retrospective study. Drug Saf, 25, 1021